Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial
Usha Perepu, Isaac Chambers, Abdul Wahab, et al.
Journal of Thrombosis and Haemostasis (2021) Vol. 19, Iss. 9, pp. 2225-2234
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

ISTH guidelines for antithrombotic treatment in COVID‐19
Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 10, pp. 2214-2225
Open Access | Times Cited: 145
Thromboprophylaxis in Patients With COVID-19
Lisa K. Moores, Tobias Tritschler, Shari B. Brosnahan, et al.
CHEST Journal (2022) Vol. 162, Iss. 1, pp. 213-225
Open Access | Times Cited: 79
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 69
Pharmacology of Heparin and Related Drugs: An Update
John Hogwood, Barbara Mulloy, R. Lever, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 2, pp. 328-379
Open Access | Times Cited: 47
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Sam Schulman, Donald M. Arnold, Charlotte Bradbury, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 6, pp. 1779-1797
Open Access | Times Cited: 18
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Luis Ortega‐Paz, Mattía Galli, Davide Capodanno, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2021) Vol. 8, Iss. 7, pp. 677-686
Open Access | Times Cited: 65
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT
Erin A. Bohula, David D. Berg, Mathew S. Lopes, et al.
Circulation (2022) Vol. 146, Iss. 18, pp. 1344-1356
Open Access | Times Cited: 65
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
Geoffrey D. Barnes, Allison Burnett, Arthur L. Allen, et al.
Journal of Thrombosis and Thrombolysis (2022) Vol. 54, Iss. 2, pp. 197-210
Open Access | Times Cited: 54
Anticoagulation in Patients With COVID-19
Michael E. Farkouh, Gregg W. Stone, Anuradha Lala, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 9, pp. 917-928
Open Access | Times Cited: 51
Anticoagulants for people hospitalised with COVID-19
Ronald Luiz Gomes Flumignan, Vinicius Tassoni Civile, Jéssica Dantas de Sá Tinôco, et al.
Cochrane library (2022) Vol. 2022, Iss. 3
Open Access | Times Cited: 50
Clinical features of thrombosis and bleeding in COVID-19
Mari R. Thomas, Marie Scully
Blood (2022) Vol. 140, Iss. 3, pp. 184-195
Open Access | Times Cited: 41
Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia
Vincent Labbé, Damien Contou, Nicholas Heming, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 6, pp. 520-520
Open Access | Times Cited: 21
Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient and post-discharge prophylaxis: a meta-analysis of randomized controlled trials
Jiahao Meng, Hang Tang, Yifan Xiao, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 8
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis
Michelle Sholzberg, Bruno R. da Costa, Grace H. Tang, et al.
Research and Practice in Thrombosis and Haemostasis (2021) Vol. 5, Iss. 8, pp. e12638-e12638
Open Access | Times Cited: 44
COVID-19 Coagulopathy: From Pathogenesis to Treatment
Teba Alnima, Mark M. G. Mulder, Bas C.T. van Bussel, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 282-296
Open Access | Times Cited: 30
COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment
Luis Ortega‐Paz, Azita H. Talasaz, Parham Sadeghipour, et al.
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 08, pp. 816-832
Open Access | Times Cited: 28
Preferences for thromboprophylaxis in the intensive care unit: An international survey
Èmese Heijkoop, Frederik Keus, Morten Hylander Møller, et al.
Acta Anaesthesiologica Scandinavica (2025) Vol. 69, Iss. 4
Open Access
Severely Ill COVID-19 Patients May Exhibit Hypercoagulability Despite Escalated Anticoagulation
Soslan S. Shakhidzhanov, A. E. Filippova, Elizaveta Bovt, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1966-1966
Open Access
Enoxaparin for thromboprophylaxis in hospitalized COVID‐19 patients: The X‐COVID‐19 Randomized Trial
Nuccia Morici, Gian Marco Podda, Simone Birocchi, et al.
European Journal of Clinical Investigation (2021) Vol. 52, Iss. 5
Closed Access | Times Cited: 37
Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis
Xiaoming Wu, Haijiao Jing, Chengyue Wang, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 25
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial
Marc Blondon, Sara Cereghetti, Jérôme Pugin, et al.
Research and Practice in Thrombosis and Haemostasis (2022) Vol. 6, Iss. 4, pp. e12712-e12712
Open Access | Times Cited: 25
Increased Susceptibility for Thromboembolic Events versus High Bleeding Risk Associated with COVID-19
Cristina Tudoran, Dana Emilia Velimirovici, Delia Berceanu-Văduva, et al.
Microorganisms (2022) Vol. 10, Iss. 9, pp. 1738-1738
Open Access | Times Cited: 25
COVID‐19 and venous thromboembolism: A narrative review
Dana E. Angelini, Scott Kaatz, Rachel Rosovsky, et al.
Research and Practice in Thrombosis and Haemostasis (2022) Vol. 6, Iss. 2, pp. e12666-e12666
Open Access | Times Cited: 23
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
John W. Eikelboom, Sanjit S. Jolly, Emilie P. Belley‐Côté, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 12, pp. 1169-1177
Open Access | Times Cited: 22
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
Stéphane Zuily, Benjamin Lefèvre, Olivier Sanchez, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102031-102031
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top